Literature DB >> 1756533

Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens.

Y S Kim1, R Slomski, E P Cohen.   

Abstract

Transfection of genomic DNA from B16 mouse melanoma into LM(TK-) fibroblasts led to the generation of several clones of transfected cells that strongly expressed B16 melanoma-associated antigens (MAA). The transfected cells retained their H-2k markers and served as allogenic cells with expressive MAA in C57BL/6 mice, syngeneic with the melanoma. The cells were capable of eliciting primary anti-B16 immune responses in vitro in spleen cells from C57BL/6 mice. Immunization of C57BL/6 mice with the transfected cells led to the generation of anti-B16 cytotoxic activity in spleen cells, and C57BL/6 mice immunized with the MAA-positive transfected cells were partially resistant to a lethal challenge with B16 melanoma cells. Under similar conditions, B16 cells were nonimmunogenic. Therefore, transfected allogeneic LM(TK-) fibroblast cells expressing MAA served as more potent anti-melanoma immunogens than the parental B16 tumor cells themselves.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1756533     DOI: 10.1007/bf01742307

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  34 in total

1.  Expression of the mouse serum albumin gene introduced into differentiated and dedifferentiated rat hepatoma cells.

Authors:  J Deschatrette; C Fougere-Deschatrette; L Corcos; R T Schimke
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

Review 2.  Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.

Authors:  P D Greenberg; J P Klarnet; D E Kern; M A Cheever
Journal:  Prog Exp Tumor Res       Date:  1988

3.  Resistance to murine leukemia in mice rejecting syngeneic somatic hybrid cells.

Authors:  W Liang; E P Cohen
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

4.  Generation of glucocorticoid-responsive Moloney murine leukemia virus by insertion of regulatory sequences from murine mammary tumor virus into the long terminal repeat.

Authors:  J Overhauser; H Fan
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

5.  Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.

Authors:  M S Mitchell; J Kan-Mitchell; R A Kempf; W Harel; H Y Shau; S Lind
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

6.  Transfection by human oncogenes: concomitant induction of tumorigenicity and tumor-associated membrane alterations.

Authors:  J G Collard; W P van Beek; J W Janssen; J F Schijven
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

7.  Tumor-specific immunity induced by somatic hybrids. I. Lack of relationship between immunogenicity and tumorigenicity of selected hybrids.

Authors:  B S Kim; W Liang; E P Cohen
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

8.  DNA-mediated transfer of human melanoma cell surface glycoprotein gp130: identification of transfectants by erythrocyte rosetting.

Authors:  A P Albino; L H Graf; R R Kantor; W McLean; S Silagi; L J Old
Journal:  Mol Cell Biol       Date:  1985-04       Impact factor: 4.272

9.  Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.

Authors:  D L Toffaletti; T L Darrow; D W Scott
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

10.  Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity.

Authors:  A Kasid; M E Lippman; A G Papageorge; D R Lowy; E P Gelmann
Journal:  Science       Date:  1985-05-10       Impact factor: 47.728

View more
  1 in total

1.  MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens.

Authors:  T S Kim; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.